The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor. The post Eli Lilly's lepodi...
Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended ap...
/PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking data from its TRILUMINATE Pivotal trial that show the TriClip transcatheter edge-to-ed...
Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a cardioprotective benefit ...
Eli Lilly's lepodisiran met Phase 2 trial goals, significantly lowering Lp(a) levels. A Phase 3 study is enrolling to assess its impact on cardiovascul...
BMS' Karen Costello talks about navigating change and challenges in the rapidly advancing biopharma sector.Read more: A day in the life of a general ma...
NEW YORK CITY (dpa-AFX) - Halozyme Therapeutics, Inc. (HALO), Monday announced that Bristol Myers Squibb (BMY) received a positive opinion from the Com...
Frequently Asked Questions about Valleyregionalimaging
Who are Valleyregionalimaging's top competitors?
Valleyregionalimaging's top 3 competitors are Greensboro Radiology, At Home Diagnostics, P+® X-ray Phantom.
Who is similar to Valleyregionalimaging?
Greensboro Radiology is the most similar to Valleyregionalimaging. At Home Diagnostics and P+® X-ray Phantom are also similar to Valleyregionalimaging.
Are Valleyregionalimaging and Greensboro Radiology competitors?
Yes, Greensboro Radiology is one of Valleyregionalimaging’s top competitors.